High-Resolution Analysis of Gene Copy Number Alterations in Human Prostate Cancer Using CGH on cDNA Microarrays: Impact of Copy Number on Gene Expression  by Wolf, Maija et al.
High-Resolution Analysis of Gene Copy Number Alterations in
Human Prostate Cancer Using CGH on cDNA Microarrays:
Impact of Copy Number on Gene Expression1
Maija Wolf*, Spyro Mousses y, Sampsa Hautaniemi z, Ritva Karhu§, Pia Huusko y, Minna Allinen b, Abdel Elkahloun b,
Outi Monni#, Yidong Chen b, Anne Kallioniemi§ and Olli-P Kallioniemi*,y
*Medical Biotechnology, VTT Technical Research Centre of Finland and University of Turku, Turku FIN-20520,
Finland; yTranslational Genomics Research Institute, Gaithersburg, MD 20878-1762, USA; z Institute of Signal
Processing, Tampere University of Technology, Tampere FIN-33101, Finland; §Laboratory of Cancer Genetics,
Tampere University Hospital and Institute of Medical Technology, University of Tampere, Tampere FIN-33520,
Finland; bCancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health,
Bethesda, MD 20892, USA; #Biomedicum Biochip Center, University of Helsinki, Helsinki FIN-00014, Finland
Abstract
Identification of target genes for genetic rearrangements
in prostate cancer and the impact of copy number
changes on gene expression are currently not well
understood. Here, we applied high-resolution compara-
tive genomic hybridization (CGH) on cDNA microarrays
for analysisof prostate cancer cell lines.CGHmicroarrays
identified most of the alterations detected by classical
chromosomal CGH, as well as a number of previously
unreported alterations. Specific recurrent regions of gain
(28) and loss (18) were found, and their boundaries
defined with sub-megabasepair accuracy. The most
common changes included copy number decreases at
13q, and gains at 1q and 5p. Refined mapping identified
several sites, such as at 13q (33–44, 49–51, and 74–76
Mbp from the p-telomere), which matched with minimal
regions of loss seen in extensive loss of heterozygosity
mapping studies of large numbers of tumors. Previously
unreported recurrent changes were found at 2p, 2q, 3p,
and 17q (losses), and at 3q, 5p, and 6p (gains). Integration
of genomic and transcriptomic data revealed the role of
individual candidate target genes for genomic alterations
as well as a highly significant (P < .0001) overall
association between copy number levels and the per-
centage of differentially expressed genes. Across the
genome, the overall impact of copy number on gene
expression levels was, to a large extent, attributable
to low-level gains and losses of copy number, corre-
sponding to common deletions and gains of often large
chromosomal regions.
Neoplasia (2004) 6, 240–247
Keywords: Copy number alteration, prostate cancer, gene expression, cDNA micro-
array, CGH microarray.
Introduction
Despite the high prevalence of prostate cancer, its molec-
ular basis continues to be poorly understood. Gene micro-
array technologies have provided a new means for exploring
the transcriptome of prostate cancer cells. This information has
been applied to distinguish patterns and gene expression
fingerprints for benign prostate hyperplasia, to identify sub-
types of prostate cancer, and to identify markers for diagnosis
and candidate targets for therapy [1,2]. In addition to the gene
expression, gene copy number changes have been shown to
be involved in the development and progression of prostate
cancer [3–6]. However, most of the target genes for the genetic
alterations remain unknown and their impact on global gene
expression profiles remains unclear [7]. Cancer cell lines are
widely used as models for tumorigenesis and progression of
prostate cancer, and their genomic and transcriptomic profiling
is relevant to understanding the molecular mechanisms under-
lying the disease.
Here, we applied cDNA microarrays to survey changes in
DNA copy number throughout the genomes of four cell lines
(PC-3, DU 145, LNCaP, and CWR22R) established from ad-
vanced prostate cancer. Gains and losses throughout the
cancer genome were examined with a cDNAmicroarray having
an average clone spacing of 280 kb, and the results were
compared and validated with data from chromosomal compar-
ative genomic hybridization (CGH) and locus-specific fluores-
cence in situ hybridization (FISH) analyses. We also sought to
define the boundaries of common copy number alterations and
to determine the impact of these alterations on gene deregu-
lation in prostate cancer.
Abbreviations: CGH, comparative genomic hybridization; FISH, fluorescence in situ hybrid-
ization; BAC, bacterial artificial chromosome
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Materials and Methods
Prostate Cancer Cell Lines and Sample Preparation
PC-3, DU 145, and LNCaP cell lines were obtained from
the American Type Culture Collection (ATCC, Manassas,
VA). CWR22R cells were kindly provided by Dr. Jim Jacob-
berger’s Laboratory at Case Western Reserve University
(Cleveland, OH). Cell culture conditions were as recommen-
ded by the supplier. For each cell line, at least four T175
flasks were pooled to obtain enough material. PolyA-RNA
was isolated from the samples using FastTrack 2.0 mRNA
isolation kit (Invitrogen, Carlsbad, CA). After adding the lysis
buffer, genomic DNA was spooled from the same sample by
swirling a glass rod in the cell lysate. After spooling, DNA
samples were subjected to phenol/chloroform purification.
cDNA Microarray Preparation
A customized 16K cDNA microarray was used for the
detection of copy number and expression level changes.
In addition to a genome-wide coverage of 11,500 clones,
4700 clones were included from regions at 2p23–p25, 5p,
8q, 10q21–q24, 11q12–q14, 12q13–q15, 17q11.2–q23,
20q, and Xcen-q13, representing common amplification
sites in human cancers. Preparation and printing of the
clones on glass slides were performed as described in
Ref. [8]. On average across the genome, the 11,500 clones
correspond to a resolution of 3.6 clones per megabasepair
(or one clone every 280 kb) with, however, much greater
density at the nine amplified regions due to the set of 4700
specific clones targeting these regions.
CGH and Expression Analysis on cDNA Microarrays
CGH on cDNA arrays was performed as described earlier
in Ref. [9] with slight modifications [10]. Briefly, 20 mg of
genomic DNA was digested overnight using AluI and RsaI
(Life Technologies, Inc., Rockville, MD). Gender-matched
DNA obtained from white blood cells of healthy individuals
was used as a reference for CGH array hybridizations.
Digested DNA samples were purified by phenol/chloroform
extraction. Six micrograms of digested cell line DNA and
reference DNA was labeled with Cy5-dUTP and Cy3-dUTP
(Amersham Biosciences, Piscataway, NJ), respectively, in a
random priming reaction using Bioprime Labeling kit (Life
Technologies, Inc.). Hybridization and washes were per-
formed as described earlier [9]. For cDNA microarray hybrid-
izations, 3 mg of test mRNA and 3 mg of reference sample,
composed of a pool from 18 different cancer cell lines, were
labeled with Cy5-dUTP and Cy3-dUTP, respectively, and
hybridizations were done as described in Ref. [10]. A laser
confocal scanner (Agilent Technologies, Palo Alto, CA) was
used to measure signal intensities from targets for both CGH
and cDNA microarray hybridizations.
Microarray Data Analysis
DeArray software (Scananalytics Inc., Fairfax, VA) was
used in image analysis [11]. Average intensities of the tumor
samples were divided by the average intensities of the
reference sample at each microarray spot after background
intensity subtraction. Within-slide normalization for both
cDNA and CGH data was done using ratio statistics [11],
followed by mean centering across the genes. After normal-
ization, both cDNA and CGH data were filtered using ratio
quality values [12] below 0.5 as a threshold for exclusion.
This quality cutpoint value has, in the past, been shown to
represent less reliable cDNA microarray measurements
due to either low signal intensity, high local background
level, uneven distribution of the target intensity, and/or small
target size.
A custom-made database was created including the
genomic sequence alignment information for all available
mRNA sequences according to the assembly by the Univer-
sity of California Santa Cruz’s (UCSC) Genome Browser
database (http://genome.ucsc.edu/) (December 2001
freeze), as well as the Unigene information obtained from
Build 146 (http://ncbi.nih.gov/). Genomic basepair localiza-
tions of the clones were retrieved by assigning each clone to
its Unigene cluster and then relating the data to the genomic
alignment of the mRNA sequence according to the largest
alignment size from the corresponding cluster. To visualize
the whole genome coverage of copy number data, we plotted
the clone-derived ratio data as a function of position along the
genome sequence for each clone individually (maximal
theoretical resolution f300 kb, depending on the region
and density of the clones). We also plotted moving averaged
ratios of adjacent clones with unique genomic positions to
improve the signal-to-background ratio. The figures shown
were plotted using 30-clone moving average ratios.
Regions of gain and loss were defined as loci where at
least two adjacent clones had a moving averaged CGH ratio
z1.05 (gain/amplification) or <0.95 (deletion). These thresh-
old values for altered copy number were determined based
on the normal variation in the control hybridizations; 98.5% of
the 30-clone averaged copy number ratios in a self-versus-
self experiment varied between ratios 0.95 and 1.05. The
breakpoints for the changes that were scored to be true
genetic alterations were then defined using individual clone
data or five-clone averaging. Integration of the transcriptomic
data with the genomic information was achieved by annotat-
ing the gene expression data on copy number ratios using
color coding—red for upregulated genes (global upper 7% of
expression ratios) and green for downregulated genes (global
lower 7% of expression ratios). Statistical significance of the
impact of gene copy number on gene expression was deter-
mined with chi-square analysis.
Chromosomal CGH
To evaluate the sensitivity and reliability of the array-
based CGH, the results were compared with the profiles
obtained from chromosomal CGH [13]. Cell line DNA sam-
ples representing the same batch of DNA extraction were
used for chromosomal and array CGH. The DNA samples
were labeled with FITC-12-dUTP (DuPont, Boston, MA) and
sex-matched normal reference DNA with Texas Red-6-
dUTP (DuPont). Six hundred nanograms of labeled cell line
DNA, 400 ng of reference DNA, and 10 mg of unlabeled Cot-1
DNA (Gibco BRL, Gaithersburg, MD) were hybridized to
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normal lymphocyte metaphase chromosomes. After over-
night hybridization and washing, the chromosomes were
counterstained with 0.5 M 4V,6-diamidino-2-phenylindole
(DAPI) in an antifade solution. Fluorescence intensities were
quantitated using an Olympus BX 50 epifluorescence micro-
scope (Olympus, Tokyo, Japan) and the Quips digital image
analysis system (Vysis, Inc., Downers Grove, IL). Based on
hybridization results from control samples (normal male
hybridized against normal female), chromosomal regions
with copy number ratios under 0.85 were considered as lost,
and above 1.2 as gained, in the chromosomal CGH analysis.
Interphase FISH Analysis
We validated copy number data from array CGH with
gene-specific FISH analyses at 1q with prominent copy
number alterations. Dual-color interphase FISH was done
for PC-3 using bacterial artificial chromosome (BAC) clones
RP11-119A2, RP11-79I7, and RP11-101I9 mapping to
1q24.3 (173 Mbp from the p-telomere), 1q25.3 (187 Mbp),
and 1q32 (205 Mbp), respectively. Clones were labeled with
SpectrumOrange (Vysis, Inc.) using random priming. Spec-
trumGreen-labeled 1p telomeric probe was used as refer-
ence. DAPI staining was performed and the mean number of
red and green signals was determined.
Results
Overviews of Copy Number Alterations by Array CGH and
Comparison with Chromosomal CGH
CGH microarray analysis revealed numerous recurrent
copy number changes in prostate cancer (Figure 1A,
Figure 1. Genome-wide copy number analysis of prostate cancer cell lines. (A) Copy number alterations in each cell line (black bars) and minimal common regions
of overlap (SRO) for gains and losses detected in at least two samples (gray bars) are indicated. Vertical bars designate chromosomal borders. Cumulative
genomic basepairs were calculated according to chromosome sizes (UCSC; December freeze 2001). Overall, hormone-refractory cell lines PC-3, DU 145, and
CWR22R manifested more unbalanced chromosomal changes than the hormone-responsive cell line LNCaP. (B) Alignment of chromosomal (bottom) and
microarray-based CGH (top) displaying the genome-wide copy number profile for PC-3. For array-based profile, averaged ratios from 30 adjacent clones (y-axis)
were plotted as a function of the position along the human genome (x-axis).
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Table 1). Of the four cell lines, PC-3 (hormone-refractory cell
line), manifested the most copy number changes (total of 97,
with 46 gains and 51 losses) including several high-level
amplifications and deletions (Figure 1B ), while LNCaP (hor-
mone-responsive cell line) had the least number of altera-
tions (4 gains and 14 losses). Comparison of the copy
number profiles showed that 92% of the amplifications
and 82% of the deletions detected by chromosomal
CGH were also detected by array-based CGH. In addi-
tion, multiple alterations not detected using chromosomal
CGH were identified by the microarray-based method. For
example, deletions at chromosomes 5 (119–138 Mbp from
the p-telomere, at 5q23.1–q31.1), 10 (89–142 Mbp,
10q23.1–q26.3), 17 (8–43 Mbp, 17p12–q21.2), and
19 (59–66 Mbp, 19q13.2–q13.33) in the PC-3 cell line were
only detectable using high-resolution array CGH (Figure 1B).
Aberrations close to telomeres and pericentromeric regions
were also significantly better visualized by array-based,
rather than conventional, CGH analysis.
Defining Critical Regions for Losses and Gains at High
Resolution by Array CGH
The most commonly deleted region in the cell lines was
13q. Three separate minimal regions of deletions were
mapped along 13q. These sites mapped to 33 to 44 Mbp
(q13.3–q14.11), 49 to 51 Mbp (q14.2–q14.3), and 74 to
76 Mbp (q22.1–q22.2) from the p-telomere (Figure 2).
These regions match with the previously found minimal loci
for loss of heterozygosity (LOH) obtained from extensive
analyses of large numbers of primary tumors [14–16]. This
illustrates that analysis of a few informative cancer cell line
Table 1. Minimal Common Regions of Overlap for Gains and Losses Detected in at Least Two Samples.
Chromosome Distance from p-Telomere (Mbp) Cytogenetic Region PC-3 CWR22R LNCaP DU 145
(A) Minimal common areas of loss
2 38–44 2p22.2–p21 X X
2 93–95 2q11.1–q11.2 X X
2 156–160 2q24.1–q24.2 X X
2 162–174 2q24.2–q31.1 X X
3 57–89 3p21.1–p11.1 X X
4 155–157 4q31.1–q32.1 X X
4 174–188 4q34.1–q35.2 X X
10 93–95 10q23.2–q23.31 X X
10 107–108 10q24.2–q24.31 X X
13 33–44 13q13.3–q14.11 X X X
13 44–47 13q14.11–q14.2 X X
13 49–51 13q14.2–q14.3 X X X
13 74–76 13q22.1–q22.2 X X X
13 78–94 13q22.3–q32.1 X X
17 36–37 17q12–q21.1 X X
18 36–47 18q12.2–q21.1 X X
19 57–62 19q13.2–q13.32 X X
19 65–66 19q13.33 X X
(B) Minimal common areas of gain
1 147–154 1q21.2–q22 X X X
1 156–161 1q23.1–q23.2 X X X
1 161–174 1q23.3–q24.3 X X
1 201–206 1q31.3–q32.1 X X
1 207–213 1q32.1–q32.2 X X
1 222–239 1q32.3–q42.13 X X
3 123–127 3q13.33–q21.1 X X
3 151–158 3q24 –q25.2 X X
5 1–4 5p15.33 X X X
5 8–11 5p15.31–p15.2 X X X
5 17–29 5p15.1–p13.3 X X
5 37–40 5p13.1–p12 X X
6 47–53 6p21.1–p12.3 X X
7 8–11 7p21.3 X X
7 18–25 7p21.1–p15.3 X X
7 46–92 7p13–p21.13 X X
7 101–104 7q22.1 X X
8 104–105 8q22.3 X X
8 123–125 8q24.12–q24.13 X X
10 59–60 10q21.1 X X
12 62 12q14.1 X X
12 108–115 12q23.2–q24.11 X X
14 25–51 14q12–q22.1 X X
14 53–77 14q22.2–q24.3 X X
14 93–101 14q32.13–q32.31 X X
17 35 17q12 X X
17 65–66 17q23.2–q23.3 X X
X 99–104 Xq22.2–q23 X X
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samples by array CGH can substantially narrow down the
regions of interest that are also relevant in clinical tumor
specimens. Other common copy number decreases seen
in half or more of the samples were mapped to specific
regions at 2p, 2q, 3p, 4q, 10q, 17q, 18q, and 19q (Figure 1A,
Table 1). Of these, previously unreported subtle alterations
included losses at 2p (38–44 Mbp, p22.2–p21), 2q (93–95
Mbp, q11.1–q11.2), 3p (57–89 Mbp, p21.2–p11.1), and
17q (36–37 Mbp, q12–q21.1).
The most common copy number increases were found at
1q (147–154 and 156–161 Mbp from pter, at 1q21.2–q22
and 1q23.1–q23.2) and 5p (1– 4 and 8–11 Mbp from pter, at
p15.33 and p15.31–p15.2). Other recurrent copy number
increases were mapped at high resolution to specific regions
at 3q, 6p, 7p, 7q, 8q, 10q, 12q, 14q, 17q, and Xq (Figure 1A,
Table 1). Novel findings include gains at 3q (123–127 Mbp,
q13.33–q21.1), 5p (1–4, 8–11, and 17–29 Mbp at p15.1–
p13.3 and 37–40 Mbp at p13.1–p12), and 6p (47–53 Mbp,
p21.1–p12.3).
In the PC-3 cell line, two distinct amplification sites were
located on chromosome 1 at 170 to 175Mbp (1q24.2–q25.1)
and 204 to 206 Mbp (1q32.1) from the p-telomere, with a
deleted region in between (Figure 3). These changes were
also seen by chromosomal CGH; however, the demarcation
of the amplified and deleted regions could not be visualized
well. We used dual-color interphase FISH to validate the
copy number changes with BAC probes specific to the three
regions and a 1pter reference probe. The average CGH and
FISH ratios (test vs 1pter reference probe count) agreed well
with one another.
Impact of Copy Number Alterations on Gene Expression
Levels
The application of cDNA microarrays as a platform for
CGH makes it possible to directly integrate information on
gene copy number (DNA) and expression (RNA) levels.
Across the genome, gene expression levels were signific-
antly influenced by copy number changes (P < .0001)
(Figure 4A). For these comparisons, we considered genes
to be overexpressed, if their normalized cDNA ratios
exceeded the 93rd percentile of all expression ratios, and
downregulated, if their cDNA ratios were below the lower
seventh percentile. Using 1.5 as a copy number cutpoint for
DNA amplification, 19.6% of the amplified genes showed a
high expression ratio. Because 6.9% of the genes with
normal copy number were upregulated, increased copy
number led to a 2.8-fold higher number of highly expressed
genes than expected. Using 0.8 as a copy number cutpoint
for a deletion, 12.1% of the genes with low copy number were
significantly downregulated, corresponding to 1.8-fold higher
percentage of genes than expected.
Integration of copy number and gene expression data
also facilitated the direct identification of candidate target
Figure 2. Smallest region of overlap for deletions at 13q detected by CGH on
cDNA microarrays. Three distinct deletions common for PC-3, LNCaP, and
DU 145 cell lines were detected at 13q13.3–q14.11, 13q14.2–q14.3, and
13q22.1–q22.2. Genomic positions are indicated as megabasepairs from the
p-telomere. Concordance with previous results from prostate cancer LOH
studies [14–16] is shown.
Figure 3. Validation of the copy number changes at 1q in PC-3. (A) Copy
number profile for chromosome 1 by chromosomal CGH displaying areas of
gain (green vertical bars) and loss (red vertical bar) in the long arm. (B and C)
Copy number profiles by CGH microarray, with moving average ratios from
30 clones (B) and actual ratios from individual clones (C). (D) Interphase
FISH was performed to validate the copy number changes with BAC probes
specific for q24.3 (RP11-119A2, image 1), q25.3 (RP11-79I7, image 2), and
q32 (RP11-101I9, image 3) (red). Copy number ratios were determined using
a reference probe from 1pter (green). The average CGH microarray ratios of
cDNA clones matching the genomic localization of the BAC probes and the
corresponding FISH ratios are displayed under the FISH images.
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genes for the genetic alterations. For example, several
genes in the amplicon at 10q22.1–q23.1 (77–89 Mbp from
the p-telomere), including annexins A7 and A11 (ANXA7 and
ANXA11), urokinase plasminogen activator (PLAU ), and vin-
culin (VCL), were significantly overexpressed (Figure 4B ).
Similarly, genes with elevated expression levels could
be identified from an amplified region at 14q12–q22.1
(at 27–51 Mbp from the p-telomere) in DU 145. These genes
included thyroid transcription factor 1 (TITF1) and mitogen-
activated protein kinase kinase kinase kinase 5 (MAP4K5 )
(Figure 4C ).
Discussion
We showed that CGH analysis on cDNA microarrays makes
it possible to achieve reliable high-resolution mapping of
unbalanced genetic alterations in prostate cancer, including
both high-level amplifications, but also low-level gains and
losses as validated here by comparisons with chromosomal
CGH and interphase FISH. As compared to chromosomal
CGH, the cDNA microarray-based CGH improved the sen-
sitivity and resolution of copy number detection so that more
than two-fold higher number of alterations could be found.
For example, complex copy number alterations over short
distances were often only detectable by array CGH, includ-
ing deletions that were located in close proximity to ampli-
fied regions, such as deletions at 5q (119–138 Mbp from
p-telomere), 10q (89–142 Mbp), 17 (8–43 Mbp), and 19q
(59–66 Mbp) in the PC-3 cell line (Figure 1B ). Besides an
overall low resolution (10–20 Mbp), chromosomal CGH is
particularly error-prone in detecting alterations in the peri-
centromeric and telomeric regions of the genome. CGH
Figure 4. Impact of copy number on gene expression in prostate cancer cell lines. (A) Impact of gene copy number (x-axis) on the percentage of genes ( y-axis)
whose expression was high (black bars) or low (gray bars) as a function of copy number alteration. High-level expression was defined as the top seventh percentile
of all expression ratios, whereas low-level expression was defined as the bottom seventh percentile. (B and C) Expression-annotated copy number profiles of
amplicons at 10q22–q23.1 in PC-3 (B) and 14q13.2–q21.3 in DU 145 (C). Color coding was used to indicate the level of expression as follows: bright red dots
indicate the upper two percentiles and dark red dots indicate the next five percentiles of the gene expression ratios in the analyzed cells (overexpressed genes),
with green color referencing to downregulated genes. Ten overexpressed and amplified genes are highlighted in both amplicons.
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microarray does not suffer from these limitations, and ena-
bles accurate detection of copy number at such regions.
CGH microarray provided an ability to accurately identify
and map the boundaries of copy number changes. For
example, at 13q, we found three distinct regions of loss,
common to PC-3, LNCaP, and DU 145, residing at 33 to
44 Mbp (q13.3–q14.11), 49 to 51 Mbp (q14.2–q14.3), and
74 to 76 Mbp (q22.1–q22.2) from the p-telomere. These
regions have been detected previously and narrowed down
with extensive allelic loss measurements, analyzing one
locus at a time [14–16]. This highlights the power of the
CGH microarray technology in rapidly identifying and nar-
rowing down regions of importance for tumor progression.
Other similar recurrent deletions that deserve further study
in large panels of tumors were found at specific regions
at 2p (38–44 Mbp), 2q (93–95 Mbp), 3p (57–89 Mbp), and
17q (36–37 Mbp).
The resolution of the array CGH is limited only by
the density of the clones on the array, which in our study
was one clone every 280 kb. This is substantially higher
than in most BAC clone–based CGH microarray studies.
However, using cDNA and other small clones as a target,
results from individual clones may not be accurate in detect-
ing low copy number gains and losses. Therefore, analysis
of moving mean ratios from adjacent clones and establish-
ment of threshold values from control experiments were
necessary to reliably score copy number alterations.
Application of cDNA microarrays in CGH is particularly
valuable in that it makes it possible to readily integrate copy
number and gene expression data across the genome. We
showed how this can be used to directly identify genes that
are activated or silenced by specific genetic alterations. We
found several amplified and highly upregulated genes that
may be critical for tumor progression. For example, at
10q22.1–q23.1, there were many candidate genes that were
both amplified and highly upregulated, including annexins A7
and A11 (calcium-dependent phospholipid-binding proteins
previously implicated as downregulated in cancer) [17,18],
urokinase plasminogen activator (a protein known to play a
role in invasion and metastasis) [19–21], as well as vinculin
(a cytoskeletal protein). Furthermore, TITF1 and MAP4K5
were overexpressed in the amplicon at 14q12–22.1. These
genes provide prioritized candidate genes for further evalu-
ation from clinical samples.
Across the genome, the impact of gene copy number
on expression levels was statistically highly significant
(P < .0001), both for regions with increased and decreased
copy numbers. This validates the importance of DNA copy
number changes in the development and progression of
prostate cancer, as shown previously in breast cancer
[22,23]. Even low-level gains and losses of copy number,
corresponding to common deletions and gains of chromo-
somal regions, had a highly significant impact on gene ex-
pression levels. Across the genome, on average, f12% of
the genes examined in the prostate cancer cell lines were
involved in unbalanced chromosomal alterations. Quantita-
tively, 63% of the impact of copy number on global gene
expression deregulation (number of genes affected multi-
plied by the fold change in gene expression) was attributable
to such simple gains and losses. These expression changes
were often small in magnitude, but the large number of genes
affected in these large regions made their contribution quan-
titatively highly significant. This indicates that changes
in gene dosage caused by common chromosomal losses
and gains may have a more significant influence on genome-
wide gene expression levels in cancer than previously
thought. Such gene expression changes may directly con-
tribute to the selection of common chromosomal alterations
in cancer [7,24,25].
In summary, our cDNA microarray-based genomic and
transcriptomic surveys provided a comprehensive integrated
view on gene copy number changes in prostate cancer,
mapped recurrent regions of interest at high resolution,
implicated candidate genes therein, as well as provided a
global view on the impact of such changes on gene expres-
sion profiles in prostate cancer.
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